Warrant Programme - New Articles of Association

Company Announcement no. 26/2014

To: NASDAQ OMX Copenhagen A/S                                 Hørsholm, Denmark, 17 November 2014

Warrant Programme - New Articles of Association

In accordance with its authorisation pursuant to Section 5A of the Articles of Association, the Board of Directors of Veloxis Pharmaceuticals A/S has on 12 November issued 300,000 warrants for the subscription of nominally DKK 30,000 shares in the Company.

The amendment of the Articles of Association associated with the issue of warrants has today been registered with the Danish Business Authority. The new Articles of Association are for Veloxis Pharmaceuticals A/S are attached.

For more information, please contact:

Veloxis Pharmaceuticals A/S

Bill Polvino                                            Johnny Stilou

President & CEO                                    EVP, Chief Financial Officer

Mobile: +1 917 647 9107                      Mobile: +45 21 227 227

Email: wjp@veloxis.com                        Email: jst@veloxis.com

About Veloxis Pharmaceuticals

Based in Hørsholm, Denmark, with an office in New Jersey, Veloxis Pharmaceuticals A/S, or Veloxis, is a specialty pharmaceutical company. Veloxis’ unique, patented delivery technology, MeltDose®, is designed to enhance the absorption and bioavailability of select orally administered drugs. Veloxis is listed on the NASDAQ OMX Copenhagen under the trading symbol OMX: VELO.

For further information, please visit www.veloxis.com.

Vedhæftede filer:

171114 Veloxis Announces Articles of Association.pdf

171114 Veloxis Articles of Association.pdf